Wide Ranks

CYTK

Cytokinetics, Incorporated

52.22

Top Statistics
Market Cap 6 B Forward PE -10.05 Revenue Growth 22.50 %
Current Ratio 9.28 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -11.85 Enterprise / Revenue 1882.34 Price To Sales Trailing12 Months 1914.47
Profitability
Profit Margins 0.00 % Operating Margins -30410.58 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 8.57 Total Debt 908 M
Total Debt To Equity Current Ratio 9.28 Book Value Per Share -0.1180
All Measures
Short Ratio 1273.00 % Message Board Id finmb_27315 Shares Short Prior Month 15 M
City South San Francisco Uuid 39e332a5-8990-3a41-9526-4fd099b8f8a6 Previous Close 52.02
First Trade Date Epoch Utc 1 B Book Value -0.1180 Beta 0.7830
Total Debt 908 M Volume 752508 Last Split Date 1 B
Fifty Two Week Low 32.35 Total Cash Per Share 8.57 Total Revenue 3 M
Shares Short Previous Month Date 1 B Target Median Price 78.00 Max Age 86400
Recommendation Mean 1.84 Sand P52 Week Change 0.3133 Operating Margins -30410.58 %
Target Mean Price 81.41 Net Income To Common -576401984 Short Percent Of Float 0.1886
Implied Shares Outstanding 118 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 1 B
Next Fiscal Year End 1 B Revenue Per Share 0.0300 Held Percent Insiders 0.0050
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 52.02 Target Low Price 60.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 53.31 Open 52.03 Free Cashflow -242420992
State CA Dividend Yield 0.00 % Return On Assets -0.3013
Time Zone Short Name EST Trailing Eps -5.38 Day Low 51.66
Address1 350 Oyster Point Boulevard Shares Outstanding 118 M Price Hint 2
Target High Price 120.00 Website https://www.cytokinetics.com 52 Week Change 0.5597
Average Volume 1 M Forward Eps -5.39 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 921.50 % Last Split Factor 1:6
Regular Market Day High 52.83 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 110.25 Day High 52.83 Shares Short 14 M
Regular Market Open 52.03 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1882.34 Revenue Growth 22.50 % Shares Percent Shares Out 0.1236
Operating Cashflow -404356992 Currency USD Time Zone Full Name America/New_York
Market Cap 6 B Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Biotechnology Long Name Cytokinetics, Incorporated
Regular Market Day Low 51.66 Held Percent Institutions 1.18 Current Price 52.22
Enterprise To Ebitda -11.85 Financial Currency USD Current Ratio 9.28
Industry Disp Biotechnology Number Of Analyst Opinions 17 Country United States
Float Shares 117 M Two Hundred Day Average 58.99 Ir Website http://phx.corporate-ir.net/phoenix.zhtml?c=142156&p=irol-IRHome
Enterprise Value 6 B Price To Sales Trailing12 Months 1914.47 Forward PE -10.05
Regular Market Volume 752508 Ebitda -511143008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

It develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.

It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.

The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.